Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue type

Abstract

Poly(3‐hexylthiophene)‐b‐poly(4‐vinylpyridine) diblock copolymer was synthesized by RAFT polymerization of 4‐vinyl pyridine using a trithiocarbonate‐terminated poly(3‐hexylthiophene) macro‐RAFT agent. The optoelectronic properties and the morphology of the block copolymer blends with CdSe quantum dots were investigated. UV‐vis and fluorescence experiments were performed to prove the charge transfer between CdSe and poly(3‐hexylthiophene)‐b‐poly(4‐vinylpyridine) diblock copolymer. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

Plasmacytic differentiation in MALT lymphomas following treatment with rituximab

“…As opposed to nodal B cell lymphomas, the data on the use of R are relatively scarce. Either R monotherapy or combinations have been tested in patients with MALT lymphoma [9][10][11]. While a randomized trial (published in abstract form) has demonstrated R plus chlorambucil to be more effective than chlorambucil alone, this has not been demonstrated for other chemotherapies and R is currently not approved for application in MALT lymphoma.…”

“…In case of more advanced disease or in patients failing HP eradication, various systemic forms of treatment have been shown to be active [7][8][9]. While the anti-CD20 antibody rituximab (R) has revolutionized the treatment of various types of B cell lymphomas, the data in patients with MALT lymphoma are still limited [10,11].…”

Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie

“…The response rate to the combination in this series © F e r r a t a S t o r t i F o u n d a t i o n was excellent, being 100% including 90% CR. 15 Furthermore, the combination of rituximab and chlorambucil has been shown to be highly effective in patients with MALT lymphoma, resulting in response rates of up to 100%, 22,23 even in gastric MALT lymphomas positive for t(11;18)(q21;q21), a known negative predictive marker for response to chlorambucil. [16][17][18] This is not, however, surprising, as it has been shown that the activity of rituximab is not dependent on t(11,18)(q21;q21).…”

A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma

“…Although its use in MALT lymphoma has not been officially approved for this indication in China, rituximab has been reported to have high effectiveness in this disease, both in monotherapy and in combination immune-chemotherapy (21,33,(39)(40)(41)(42). Furthermore, according to a recent histologic study performed on a patient treated rituximab before receiving thoracic surgery for non-small cell lung cancer, rituximab showed its capability of penetration into lung tissue, and its high efficiency in depleting B cells in normal lung tissue, lung tumor and lung-related LNs (43).…”